GLP-1 drugs like semaglutide and tirzepatide are delivering health benefits that go far beyond their original purpose of controlling blood sugar and weight. Clinicians across the country are reporting dramatic improvements in conditions ranging from rheumatoid arthritis to sleep apnea, prompting researchers to rethink what a single medication can accomplish. While these findings are exciting, experts emphasize that many benefits fade once patients stop taking the drugs, and serious side effects remain a concern.

What Health Conditions Are Showing the Most Promise?

The list of potential benefits keeps growing as doctors observe unexpected improvements in their patients. One endocrinologist at the University of Toronto reported that patients with rheumatoid arthritis experienced dramatic anti-inflammatory effects within a week of starting treatment, even without significant weight loss . Beyond joint health, clinicians have documented improvements in blood pressure, sleep apnea, joint pain, liver disease, and possibly heart disease, asthma, and addiction .

The medications work through different mechanisms. Ozempic and Wegovy are semaglutides, which are synthetic versions of GLP-1 that regulate blood sugar and signal fullness. Mounjaro and Zepbound are tirzepatides, which mimic GLP-1 and also act on a second hormonal pathway called GIP, or glucose-dependent insulinotropic polypeptide, potentially enhancing their effects .

How Are These Drugs Protecting Major Organs?

Recent clinical trials have shown that GLP-1 drugs offer significant protection for the heart, kidneys, and liver, three of the body's most vital organs.

• Kidney Protection: A clinical trial with more than 3,500 participants found that semaglutide dramatically reduced the risk of kidney complications in people with Type 2 diabetes and chronic kidney disease. The study was stopped early due to strong findings, and the FDA approved Ozempic in January 2025 to treat chronic kidney disease in people who also have Type 2 diabetes .
• Heart Disease Prevention: The FDA approved semaglutide for cardiovascular disease in overweight or obese individuals in March 2024. A November 2023 study in the New England Journal of Medicine found that semaglutide reduced the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, by about 20% in overweight or obese adults who already had established cardiovascular disease but not diabetes .
• Liver Disease Improvement: A 2025 study funded by Novo Nordisk found that semaglutide significantly improved outcomes for people with metabolic dysfunction-associated steatohepatitis, or MASH, and liver fibrosis. One recent study focused on HIV patients, who can be vulnerable to liver disease as a side effect of some treatments, and found that liver fat fell by 31% in patients taking semaglutide for six months .

In August 2025, the FDA granted accelerated approval to semaglutide for treating MASH in adults with moderate to advanced liver scarring .

For heart failure specifically, another trial showed that tirzepatide lowered the risk of serious heart-related problems and improved overall health in patients with obesity and a type of heart failure known as heart failure with preserved ejection fraction .

What About Sleep and Brain Health?

Two major clinical trials have demonstrated that tirzepatide improved symptoms of obstructive sleep apnea in people with obesity. Being overweight or obese is the top risk factor for this condition, which affects millions of Americans. The results were so promising that in December 2024, the FDA made Zepbound the first approved treatment for moderate to severe obstructive sleep apnea in adults .

On the cognitive front, research has been more mixed. A paper published in January 2025 using data from nearly 2.5 million patients found that people prescribed GLP-1 drugs had a lower relative risk of developing dementia compared with those who took other drugs for diabetes . An analysis of medical records from more than 100 million US patients showed that taking Ozempic was linked to a lower risk of cognitive problems, and another study found that taking liraglutide, an older GLP-1 drug, was tied to much slower cognitive decline .

However, in November, Novo Nordisk announced that its two largest gold-standard randomized trials involving people with mild cognitive impairment or dementia showed that semaglutide conferred no cognitive benefits. Researchers have not abandoned the idea, though; some scientists have suggested the trials may have come too late in the course of illness, and that the drugs might prove more effective if taken before symptoms develop .

What Are the Important Limitations and Risks?

Despite the promising benefits, these medications come with significant caveats. The most important one is that many of these effects fade once patients stop taking the drug. Weight regain can start within weeks of stopping the medication, and studies suggest many patients regain much of the weight within a year .

A new study published in BMJ Medicine showed that even a short break from the drugs significantly increases the risk of heart attack, stroke, and death compared with staying on the medicines, and the effects may not be fully reversible .

Rare but serious complications have also been reported, including stomach paralysis, a condition in which the stomach stops moving food normally, and an unusual eye disorder that can threaten vision. In March, researchers at the annual meeting of the American Academy of Orthopaedic Surgeons reported a link between GLP-1 use and osteoporosis and tendon tears .

"I have patients who email me and they say, 'I've had rheumatoid arthritis, and my hands are a mess,' and then take these drugs and now, a week later, they feel brand new. There's no weight loss, but they are getting these dramatic anti-inflammatory effects," said Daniel Drucker, an endocrinologist at the University of Toronto who has studied GLP-1s for decades.

Daniel Drucker, Endocrinologist at the University of Toronto

What Does This Mean for the Future of Medicine?

The emerging benefits of GLP-1 drugs are forcing scientists to rethink what a single medication can accomplish. Beyond metabolism, these medications appear to influence inflammation, the immune system, and brain function, revealing how interconnected these systems may be. What began as a treatment for high blood sugar and body weight now offers a window into the broader architecture of human health and hints at ways medicine might address diseases once considered entirely separate .

The key takeaway for patients considering these medications is that while the benefits are real and sometimes dramatic, they require ongoing use to maintain. Anyone interested in GLP-1 therapy should discuss both the potential benefits and the risks with their healthcare provider, and understand that these drugs are not a one-time solution but rather a long-term treatment commitment.